Misplaced Pages

Olanzapine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Jfdwolff (talk | contribs) at 23:16, 17 June 2004 (site descriptors). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 23:16, 17 June 2004 by Jfdwolff (talk | contribs) (site descriptors)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Olanzapine (Zyprexa® or in a combination with fluoxetine as Symbyax®) is one of the most commonly used atypical antipsychotics. Olanzapine has been FDA approved for the treatment of schizophrenia, acute mania in bipolar disorder, and as maintenance treatment in bipolar disorder. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company.

In December 2003 the FDA approved Symbyax to treat the depressive phase of bipolar disorder.

Uses

Since the ascendancy of atypical antipsychotics, olanzapine has become a frequently-used first line agent for acute psychosis and schizophrenia.

Side effects

Common side effects include extrapyramidal symptoms: muscle rigidity, stiffness and twitches, restlessness and sedation. Weight gain, obesity and diabetes mellitus are longer-term concerns that may affect the development of cariovascular disease later on in life.

Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome, although at a much reduced rate when compared to the classical antipsychotics.

External links

Category: